Clinical Trial

A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Study acronym: Magic-C002
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-08.
Status change: Not Yet Recruiting → Recruiting 2026-01-16
Trial Details
NCT Number NCT06976190
Lead Sponsor Shanghai Miracogen Inc.
Conditions Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment 446 participants
Start Date 2025-05-06
Primary Completion 2029-05 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-20